Core Insights - Labcorp Holdings Inc. (LH) is a leading global life sciences company with a market cap of $22.9 billion, providing diagnostic, drug development, and laboratory services [1] Financial Performance - LH is expected to report Q3 earnings of $4.12 per share, a 17.7% increase from $3.50 per share in the same quarter last year, having surpassed Wall Street's estimates for the past four quarters [2] - For fiscal 2025, earnings are projected to be $16.30 per share, an 11.9% increase from $14.57 in fiscal 2024, with further growth expected to $17.89 per share in fiscal 2026, representing a 9.8% year-over-year increase [3] Stock Performance - LH stock has increased by 31.9% over the past 52 weeks, outperforming the S&P 500 Index's 17.9% gain and the Health Care Select Sector SPDR Fund's 4.5% decline during the same period [4] - Following the release of strong Q2 2025 results, LH shares rose by 6.9%, with adjusted EPS of $4.35 and revenues of $3.53 billion exceeding consensus estimates [5] Analyst Ratings - The consensus opinion on LH stock is highly optimistic, with a "Strong Buy" rating from 14 out of 18 analysts, while four recommend a "Hold," and the average price target is $296.70, indicating a 6.1% potential upside [6]